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Patients (n = 533) who participated in the Interuniversity 
Cardiology Institute of the Netherlands Trial were followed 
up for 3 to 7 years. The 5 year survival rate after throm- 
bolytic therapy with intracoronary streptokinase was 81% 
(269 patients) compared with 71% after conventional ther- 
apy (264 patients). The greatest improvement in survival 
was observed in patients with anterior infarction (81% 
versus 64% with thrombolytic therapy or conventional 
therapy, respectively), in those with heart failure on admis- 
sion or a previous infarction and in those with extensive 
myocardial ischemia on admission. Left ventricular ejec- 
tion fraction at the time of hospital discharge was better 
after thrombolytic therapy. In the hospital survivors, long- 
term outcome was related to left ventricular function at the 
time of discharge and, to a lesser extent, to the underlying 
coronary artery disease. The initial therapy (thrombolysis 
or conventional) was not an independent additional deter- 
minant of long-term survival when left ventricular function 
and coronary status at the time of hospital discharge were 
taken into account. Thus, the salutary effects of throm- 
bolytic therapy appear to be the result of myocardial 
salvage. 
Reinfarction within 3 years was observed more fre- 
quently after thrombolytic therapy, particularly in patients 
with inferior wall infarction and those with ~90% stenosis 
of the infarct-related vessel at discharge. Coronary bypass 
surgery and coronary angioplasty were performed more 
frequently after thrombolytic therapy than in convention- 
ally treated patients. At 5 years, approximately 40% of 
patients in both groups had an uneventful course without 
reinfarction or additional revascularization procedures. 
These observations demonstrate that the benefits of 
thrombolytic therapy are maintained throughout 5 years of 
follow-up. Treatment after hospital discharge of patients 
who underwent thrombolytic therapy on admission should 
not necessarily be different from conventional management 
after myocardial infarction. 
(J Am Co11 Cardiol1989;14:1609-15) 
Early thrombolytic therapy with intracoronary streptokinase 
(l-3), intravenous streptokinase (4-6), anisoylated streptoki- 
nase-plasminogen complex (APSAC) (7) or recombinant 
tissue-type plasminogen activator (rt-PA) (8-10) improves 
early and 1 year survival rates in certain groups of patients 
with acute myocardial infarction. To verify whether the 
improved survival after thrombolytic therapy is maintained 
over time, survival status was assessed after 3 to 7 years in 
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the 533 patients who were enrolled in the Interuniversity 
Cardiology Institute of the Netherlands Trial comparing 
treatment with intracoronary streptokinase and conventional 
therapy. Univariate and multivariate analyses were per- 
formed to determine which baseline characteristics were 
related to long-term survival. Furthermore, similar analyses 
were performed to identify those factors that determined 
long-term survival in patients who were discharged after 
thrombolysis or conventional therapy. 
Methods 
Patient recruitment. Between May 1981 and March 1985, 
a total of 533 patients were enrolled in a randomized trial 
comparing early thrombolytic therapy with intracoronary 
streptokinase (269 patients) and conventional treatment (264 
61989 by the American College of Cardiology 
1610 SIMOONS ET AL. JACC Vol. 14, No. 7 
LONG-TERM BENEFIT OF THROMBOLYTIC THERAPY December 1989:1609-15 
patients). Patients with electrocardiographic (ECG) evi- 
dence of myocardial infarction (1,2) who were admitted 
within 4 h of the onset of symptoms were included in the 
trial. Details of patient characteristics (l), angiography and 
other procedures (2,ll) and ECG findings (12,13) have 
previously been reported. Briefly, patients in five participat- 
ing hospitals were randomly allocated to conventional ther- 
apy or intracoronary streptokinase (250,000 U in 1 h). In 98 
patients admitted after January 1984, angiography and intra- 
coronary streptokinase were preceded by streptokinase 
(500,000 U) given intravenously. Angiography was not per- 
formed in 35 patients despite allocation to streptokinase 
therapy because of patient refusal, early death or technical 
reasons (1). Immediate coronary angioplasty was attempted 
as part of the reperfusion procedure in 46 patients (2). 
Data analysis was based on initial treatment allocation. 
Coronary arteriography and left ventriculography were per- 
formed between 10 and 40 days after admission. Left ven- 
tricular ejection fraction could be measured and the status of 
the infarct-related vessel could be assessed in 422 patients. 
Angiographic data were not available in 44 patients who 
died, 37 patients who underwent coronary bypass surgery 
before discharge and 30 patients for various other reasons. 
Follow-up. In May 1988, survival status was assessed in 
all patients through the municipal registries. In addition, 
cardiologists or general practitioners, or both, were con- 
tacted to obtain information on hospital admissions, reinfarc- 
tion and revascularization procedures. 
Statistical analysis. Survival curves for the different sub- 
groups were obtained, as described by Kaplan and Meier 
(14). Cox’s proportional hazard mode (15) was used to 
identify factors that were related to long-term survival or 
reinfarction. In a stepwise procedure, variables were in- 
cluded in the model if the probability (p) value for inclusion 
was ~0.10. A variable was removed if the p value for 
removal was >O. 15. 
Two different models were developed. In the first model, 
the association between long-term survival and patient char- 
acteristics was analyzed, including the patient history, delay 
between onset of symptoms and hospital admission, baseline 
ECG, clinical state on admission and allocation to thrombol- 
ysis or conventional therapy. Forty-five patients were ex- 
cluded from this analysis because the ST segment elevation 
in the baseline ECG could not be interpreted (12,13). A 
second model was developed to predict long-term survival in 
422 hospital survivors in whom all inforplation at the time of 
discharge (including the angiographic data) was available. 
Results 
Medication during follow-up. Three year follow-up data 
were complete in all except in two patients in whom the last 
available follow-up data were used. Medication used at 
different follow-up intervals is presented in Table 1. All 
Table 1. Medication at 1, 3 and 5 Year Follow-Up Study* 
Follow-up Year 
Medical Therapy (%) 1 3 5 
Coumarin 
Platelet aggregation inhibitors 
Beta-blockers 
ACE inhibitors 
Digoxin 
Diuretic drugs 
None 
C 16 16 16 
T 15 14 13 
C 3 4 3 
T I 5 6 
C 21 18 17 
T 20 18 14 
C 1 2 4 
T 1 2 4 
C 6 5 5 
T 5 4 3 
C 15 12 12 
T 11 10 12 
C 7 9 10 
T 9 15 17 
*The percent of patients using a given class of drugs is presented for 1, 3 
and 5 year survivors allocated to conventional therapy (C) or thrombolysis 
(T). ACE = angiotensin-converting enzyme. 
patients were treated with heparin or coumarin until hospital 
discharge. Aspirin was not routinely prescribed after dis- 
charge. Prophylactic long-term beta-adrenergic blockade 
was advised, unless contraindicated. Nevertheless, only 
20% of patients used a beta-blocker at 1 year. There were 
more patients without medication in the thrombolysis group, 
although this was not statistically significant. 
Survival (Fig. 1). Of the 269 patients allocated to throm- 
bolytic therapy, 233 (87%) were alive at the 3 year follow-up 
study, while only 207 (79%) of the 264 patients given 
conventional therapy survived to 3 years. Estimated 5 year 
survival rates were 81 and 71%, respectively. Overall reduc- 
tion in mortality during the 5 year follow-up period was 39%, 
Figure 1. Survival analysis of all 533 patients allocated to intracor- 
onary streptokinase or conventional therapy (control). Numbers 
denote patients at risk at the various intervals after treatment with 
streptokinase (top) or conventional therapy (below). Follow-up data 
were complete at 3 years. 
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Table 2. Factors Related to Survival After Conventional Therapy Table 3. Prediction of 3 Year Survival From Baseline 
(C) or Intracoronary Streptokinase (T) in 533 Patients Characteristics in 488 Patients 
Survival @) at 
Follow-up Year* 
- 
No. I 3 5 
All patients 
Infarct location (on 
admission ECG) 
Anterior 
Inferior 
Admission delay (hl 
<2 
2 to 4 
ST segment deviation ton 
admission) (mV) 
Z ST <I.? 
2 ST >I.2 
Subgroups of thrombolysis 
No ic therapy 
ic SK only 
iv t ic SK 
ic SK t PTCA 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
c 
7 
T 
1 
T 
T 
264 84 79 71 
269 90 87 81 
116 78 71 64 
130 89 85 81 
148 89 85 76 
130 91 88 82 
200 83 78 72 
192 91 89 79 
64 84 79 67 
17 90 87 83 
96 87 87 78 
II6 92 92 86 
147 82 75 65 
129 89 84 78 
35 86 83 7s 
I12 88 86 83 
76 92 85 _ 
46 96 94 78 
No. of 
Patients 
3 Year 
Survival 
(%/cl 
Regression 
Coefficient 
(Cox 
C T C T analysis) 
Killip class 
l-2 
3-4 
Previous myocardial 
infarction 
No 
Yes 
Z ST segment elevation 
(mV) 
il.? 
>I.? 
Infarct location 
Inferior 
Anterior 
Treatment 
Conventional 
Thrombolysis 
Age tyrl 
<55 
>55 
Delay (h) 
<2 
2 to 4 
232 23s 81 
11 IO 29 
189 200 83 
54 45 67 
96 II6 84 
I47 129 76 
138 129 84 
I05 II6 73 
243 _ 79 
_ 245 _ 
103 103 84 
140 142 76 
184 173 78 
59 72 79 
-1.52 
88 
66 
-1.02 
91 
70 
-0.61 
90 
85 
-0.60 
89 
85 
-0.56 
_ 
87 
-0.45 
90 
85 
-0.33 
89 
87 
*Three year follow-up data were complete; 5 year data were estimated by 
Cox regression analysis. Note that ST segment elevation could not be 
assessed in 45 patients, as described previously (13,14). In the lower part of 
the table. survival data are presented as related to the actual therapy 
administered in patients allocated to thrombolysis: patients who did not 
undergo intracoronary therapy (ic), patients with intracoronary therapy only, 
those in whom intracoronary therapy was preceded by intravenous streptoki- 
nase (iv SK) and patients who underwent immediate coronary angioplasty 
(PTCA) as part of the reperfusion strategy (1). Intravenous administration of 
streptokinase was started in 1984: thus, 5 year follow-up data are not available 
in this subgroup. ECG = electrocardiogram. 
as estimated by Cox analysis (95% confidence interval 12 to 
58%). 
The diflerence between survival in the two treatment 
groups increased somewhat over time (Fig. 1). In fact, in 
those patients who were alive after 1 year, the 5 year 
survival rate was 87% after thrombolysis and 81% after 
conventional therapy. In patients with inferior infarction, a 
small but statistically nonsignificant difference in survival 
was maintained, favoring thrombolytic therapy (Table 2). 
Patients with anterior infarction particularly benefited from 
thrombolytic therapy, with 14% greater survival at 3 years 
and 17%) at 5 years. The gain in 3 year survival with 
thrombolytic therapy appeared greater in patients treated 
within 2 h of the onset of symptoms and in patients with 
extensive myocardial ischemia (ST segment elevation > I .2 
mV) on admission. At 5 years, these effects were less 
Abbreviations as in Table I. 
apparent, but these data are less reliable because of incom- 
plete follow-up information. In patients allocated to throm- 
bolytic therapy, the 3 year survival rate was 96% in 65 
patients whose infarct-related artery was patent on immedi- 
ate angiography. The survival rate was 89% in 133 patients 
whose artery opened during intracoronary administration of 
streptokinase with or without mechanical perforation of the 
occlusion. The lowest 3 year survival rate (67%) was found 
in 36 patients with a persistent occlusion despite the inter- 
vention. 
As explained in “Methods,” four different modes of 
therapy were actually administered to patients allocated to 
thrombolysis. The 3 year survival rate was lowest (83%) in 
35 patients to whom intracoronary streptokinase was not 
given. There was no difference between patients treated with 
or without intravenous streptokinase before intracoronary 
thrombolysis (85 versus 86% 3 year survival, respectively). 
The highest 3 year survival rate (94%) was observed in 46 
selected patients who underwent angioplasty as part of the 
reperfusion strategy. 
The results of multivariate analysis (using the Cox model) 
of the effect of thrombolytic therapy on survival are pre- 
sented in Table 3. The greatest gain in survival was achieved 
in patients with impaired left ventricular function (Killip 
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Figure 2. Distribution of new events during the follow-up period: 
recurrent myocardial infarction, coronary bypass surgery (cabg) and 
coronary angioplasty (ptca) at 1 year intervals. Bars indicate the 
number of events in each year. Open bars = conventional therapy; 
solid bars = streptokinase. 
class 3 or 4 and previous infarction) and extensive anterior 
wall ischemia (ST segment elevation). Furthermore, age and 
the delay between symptom onset and hospital admission 
(and treatment) were predictors of late mortality. 
Reinfarction (Fig. 2 and 3). Early reinfarction (within 1 
year after admission) was more frequent after thrombolysis 
compared with conventional therapy (13 versus 5%) (Fig. 2), 
particularly in patients with inferior infarction (1). Few 
reinfarctions were reported in the subsequent 2 years, while 
the rate seemed to increase during years 4 and 5 in conven- 
tionally treated patients (Fig. 3). The total incidence of 
reinfarction after 5 years was the same in the two treatment 
groups. A predischarge exercise test was performed in 400 
patients and showed angina or ST segment depression, or 
both, in 167. Recurrent infarction occurred in 30 (18%) of the 
167 patients with ischemia during exercise and 50 (21%) of 
the 233 patients without ischemia. Also, the risk of the 
combined end point (reinfarction or death) was not enhanced 
in patients with ischemia during exercise compared with 
those without ischemia (26 versus 33%). These differences 
were not statistically significant. 
30 x RECURRENT MYOCAROIAL INFARCTION 
STREPTOKINASE 
c___l 
10 ;.I 
,I 
:--------- 
: _ ‘ _ ~ _ _ _ ‘ _ ‘ _ ‘ _ ‘ _ ’  CONTROL 
rJ--f.i-‘---- 
UJ , 
0 1 2 3 4 5 
YEARS 
Figure 3. Cumulative rate (%) of first reinfarction observed in 
surviving patients with a 3 to 5 year follow-up period. 
Revascularization procedures (Fig. 2). Coronary angio- 
plasty and bypass surgery for postinfarction angina were 
more frequent in the first 3 years after thrombolytic therapy. 
A revascularization procedure was required in 35% of pa- 
tients treated with thrombolytic therapy and in 27% treated 
with conventional therapy. In both groups, the event-free 
survival rate without reinfarction, angioplasty or bypass 
surgery was similar. More than half of the patients had an 
event-free 3 year survival and approximately 40% survived 
more than 5 years without reinfarction or an additional 
revascularization procedure. 
Predictors of survival and reinfarction (Table 4). To as- 
sess which factors determine long-term survival after throm- 
bolytic therapy, data were analyzed in the 422 hospital 
survivors with complete angiographic data. Cox regression 
analysis revealed that left ventricular ejection fraction be- 
tween days 10 and 40 was the best predictor of long-term 
survival in both patient groups. Other predictors were the 
severity of the stenosis of the infarct-related coronary artery 
and either the extent of coronary disease or age and a history 
of previous infarction. It should be noted that the original 
allocation to thrombolytic or conventional therapy carried 
no predictive value in addition to the factors mentioned. For 
example, the survival curves of patients in both groups with 
a similar left ventricular ejection fraction at angiography 
between days 10 and 40 virtually overlap (Fig. 4). Thus, the 
long-term benefit of thrombolytic therapy could be explained 
by the better left ventricular function and the lower number 
of patients with an occluded vessel. Patients who were 
discharged with preserved left ventricular function and no 
remaining stenosis >50% had a 95% chance of 5 year 
survival (Fig. 5). This group included 97 (23%) of the 422 
patients with complete data. In contrast, the estimated 5 
year survival rate was only 55% in 76 patients discharged 
with impaired ventricular function and either a severe resid- 
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Table 4. Observed (1 to 3 year) and Estimated (5 year) Survival 
Rates in 422 Patients With Angiography Between Days 10 and 40 
Follow-up Year 
Angiography No. I 3 5 
Left ventricular ejection 
fraction (76) 
>40 
<40 
Infarct-related vessel 
stenosis (777) 
<90 
>90 
Vessels with stenosis X0% 
oto I 
2 to 3 
Age (yr) 
<55 
>S5 
Previous infarction 
No 
Yes 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
C 
T 
I45 96 94 86 
184 98 97 83 
49 87 72 51 
44 90 78 65 
55 
132 
139 
96 
97 
99 
92 
92 
98 
99 
91 
93 
95 
99 
93 
94 
95 
98 
88 
88 
93 80 
98 94 
86 78 
86 78 
84 
124 
II0 
104 
95 79 
98 92 
83 77 
86 XI 
88 
96 
106 
132 
91 83 
97 95 
87 76 
89 XI 
I54 
I84 
40 
43 
91 84 
96 92 
78 62 
79 62 
C = conventional therapy; T = thrombolysis. 
Figure 4. Survival of patients with left ventricular ejection fraction 
(EF) ~40% (GE), 30 to 39% and ~30% (LT) as measured by 
contrast angiography between days 10 and 40. No difference was 
observed between patients treated with streptokinase (continuous 
lines) or conventional therapy (dotted lines) within a given range of 
ejection fraction. 
% SURVIVAL 
EF GE 40% 
.._._._..._. . I 
‘__- “-.-‘-‘I._..._.~,_,_,_ 
LT 30% 
0 J c-------_ 
0 1 2 3 4 5 
YEARS 
60 % 5 years mortality 
+ + + + - - - - lvef ( 40% 
+ + - - + + - - IT” ) 90% 
+-+-+-++ vd 2-3 
Figure 5. Prediction of the 5 year mortality rate (%) by Cox 
regression analysis based on left ventricular ejection fraction (lvef), 
the extent of coronary artery disease and the status of the infarct- 
related vessel (irv) (HO% stenosis) as assessed at hospital dis- 
charge. The height of each bar corresponds with the predicted 
mortality rate, and the number in each bar indicates the number of 
patients in that particular subgroup. The asterisks indicate the 
actually observed 5 year mortality rate in each subgroup. This 
analysis was performed in 422 patients with angiography between 
days 10 and 40. vd 2-3 = patients with double or triple vessel 
coronary artery disease. 
ual stenosis of the infarct-related vessel or double or triple 
vessel narrowing, or both. 
Predictors of reinfarction by multivariate analysis were 
initial therapy with streptokinase, inferior location of the 
infarction and a residual stenosis >90% in the infarct-related 
vessel. Predictors of the combined end point of death or 
reinfarction were left ventricular ejection fraction, 290% 
stenosis of the infarct-related vessel and a history of previ- 
ous infarction. 
Discussion 
Role of thrombolytic therapy in long-term survival. The 
present data demonstrate, for the first time, the sustained 
benefits of thrombolytic therapy up to 5 years after random- 
ization. Earlier reports were confined to a 1 year follow-up 
period (1,6,7) or to a comparison of so-called “successful” 
and “nonsuccessful” thrombolysis (16). The long-term fol- 
low-up data confirm our earlier report (13) that the gain in 
survival was greatest in patients with impaired left ventric- 
ular function on admission and a large anterior infarction 
treated early after the onset of symptoms. Nevertheless, 
thrombolytic therapy was also effective in patients with 
inferior wall infarction. The decision whether thrombolytic 
therapy is warranted in a given patient should be based on a 
cost-effect analysis of data from this and other studies 
(17,181. 
There were no differences in the clinical features between 
the two treatment groups at hospital admission (1). Throm- 
bolytic therapy with intracoronary streptokinase resulted in 
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limitation of infarct size, preservation of global and regional 
left ventricular function and an improved hospital survival 
rate (1,2,11). The difference in long-term survival rates could 
fully be explained by differences in left ventricular function 
and development of further coronary artery disease at hos- 
pital discharge. Given these established predictors of long- 
term survival, the initial therapy had no further independent 
predictive value for survival. After the initial 3 months, the 
mortality and reinfarction rates leveled off in both patient 
groups (Fig. 2), whereas the rate of reinfarction seemed to 
increase again after 4 years (Fig. 3). This suggests that the 
initial course is determined by the treatment of the infarc- 
tion, while long-term prognosis is related to the further 
development of coronary artery disease. 
Role of coronary thrombolysis and angioplasty. It should 
be appreciated that this trial was performed during a period 
when the methods for thrombolytic therapy developed rap- 
idly. Accordingly, the actual therapy given to patients allo- 
cated to thrombolysis differed (Table 2). Nevertheless, the 
principle was maintained to compare a strategy of throm- 
bolytic therapy with conventional management of myocar- 
dial infarction, and the data were analyzed according to the 
“intention to treat” principle. In a selected subgroup of 
patients, immediate coronary angioplasty was performed as 
part of the reperfusion strategy. These patients fared better 
than the other patients after thrombolytic therapy. To ac- 
count for differences in baseline characteristics of patients 
with and without immediate angioplasty, a matched pair 
analysis was performed (19), which demonstrated no effect 
on infarct size or left ventricular function after angioplasty, 
although recurrent ischemic episodes and reinfarction were 
reduced. Recently, the effects of systemic immediate or 
early coronary angioplasty were analyzed in three studies 
(20-22). Systematic angioplasty 18 to 48 h after thrombolysis 
in patients with suitable anatomy did not improve the 1 year 
survival rate, as recently reported by the Thrombolysis in 
Myocardial Infarction (TIMI) investigators (20), whereas 
immediate angioplasty in all patients (21) and patients with 
suitable anatomy (22) had no benefit in terms of infarct size, 
left ventricular function or survival compared with throm- 
bolytic therapy with t-t-PA without mechanical intervention. 
Indications for an additional revascularization procedure. 
The improved long-term survival after thrombolytic therapy 
may be related in part to more frequent bypass surgery and 
coronary angioplasty in these patients. These additional 
revascularization procedures were performed only in pa- 
tients with angina or otherwise documented myocardial 
ischemia. One might speculate whether the long-term prog- 
nosis after thrombolytic therapy, as presented in this report, 
could be further improved by more extensive revasculariza- 
tion in a greater number of patients. The data in Figure 5 
indicate a good prognosis in all patients with preserved left 
ventricular function and only a small (7%) difference in the 5 
year survival rate among the patients in this group with and 
without residual coronary artery disease. Thus, it can be 
predicted that the benefits of additional interventions in 
these patients will only be small, particularly when the risks 
of angioplasty or bypass surgery are taken into account. The 
potential benefits of additional revascularization appeared 
greater in patients with impaired left ventricular function 
(Fig. 5). This is in agreement with earlier observations that 
elective coronary bypass surgery in patients with mild an- 
gina has little or no effect on survival (23), except in those 
patients with markedly impaired left ventricular function 
(24). Our present clinical practice is still to follow-up patients 
after myocardial infarction closely and to perform angio- 
plasty or surgery in patients with signs of recurrent myocar- 
dial ischemia. The presented data indicate that this policy 
should be the same whether or not thrombolytic therapy has 
been given as initial therapy. 
Medical therapy after thrombolysis. In the present study, 
medical treatment was similar after thrombolysis or conven- 
tional therapy (Table 1). Beta-blockers were prescribed in 
20% of the patients at 1 year, and anticoagulants were given 
to those patients with a severely damaged ventricle or mitral 
incompetence. Aspirin or other platelet aggregation inhibi- 
tors were infrequently used. On the basis of recent informa- 
tion, it seems likely that systematic treatment with aspirin 
and beta-blockers would further reduce the incidence of 
early reinfarction (6,25) and thereby further improve long- 
term survival (26). 
Conclusion. In all patient groups, a consistent reduction 
in the mortality rate was observed at the 5 year follow-up 
evaluation after thrombolytic therapy with intracoronary 
streptokinase. Because long-term outcome was related to 
left ventricular function and the extent of coronary artery 
disease on discharge, and not to the therapy given on 
admission, it seems likely that other thrombolytic regimens 
will have similar results. Thus, it can be expected that the 
improved early and 1 year survival rates obtained with 
intravenous streptokinase (4-6), APSAC (7) and t-t-PA (8-10) 
will also be maintained at longer follow-up intervals. 
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